OTCMKTS:BMXMF bioMerieux (BMXMF) Stock Price, News & Analysis $87.75 0.00 (0.00%) As of 10/9/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and TrendsShort Interest About bioMerieux Stock (OTCMKTS:BMXMF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get bioMerieux alerts:Sign Up Key Stats Today's Range$87.75▼$87.7550-Day Range$78.99▼$88.6752-Week Range$77.00▼$132.52VolumeN/AAverage Volume190 shsMarket Capitalization$10.39 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management. Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety. Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics. Headquartered near Lyon, France, the company serves customers internationally through operations and commercial networks across major global markets. Alexandre Mérieux serves as chairman of the company, which remains closely associated with the Mérieux family.AI Generated. May Contain Errors. Read More Receive BMXMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioMerieux and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMXMF Stock News HeadlinesbioMerieux (0RUG) Gets a Hold from BarclaysOctober 2, 2026 | theglobeandmail.combioMerieux (OTCMKTS:BMXMF) Stock Rated "Reduce" by Sell-Side BrokeragesOctober 1, 2026 | americanbankingnews.comFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.October 10 at 1:00 AM | Monetary Gold (Ad)UBS Sticks to Its Hold Rating for bioMerieux (0RUG)July 30, 2026 | theglobeandmail.comBarclays downgrades bioMerieux (0RUG) to a HoldMarch 17, 2026 | theglobeandmail.comBioMerieux SA (BMXMF) Full Year 2025 Earnings Call Highlights: Strong Organic Growth and ...February 27, 2026 | finance.yahoo.combioMerieux price target lowered to EUR 112 from EUR 113 at Morgan StanleyDecember 16, 2025 | msn.comBioMerieux upgraded to neutral from underperform at BofADecember 12, 2025 | msn.comSee More Headlines BMXMF Stock Analysis - Frequently Asked Questions How have BMXMF shares performed this year? bioMerieux's stock was trading at $129.25 on January 1st, 2026. Since then, BMXMF shares have decreased by 32.1% and is now trading at $87.75. How do I buy shares of bioMerieux? Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryN/A Current SymbolOTCMKTS:BMXMF CIKN/A Webwww.biomerieux.com Phone33-04-78-87-20-00Fax33-04-78-87-20-90Employees14,600Year Founded1963Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$4.60 billion Price / Sales2.26 Cash Flow$9.47 per share Price / Cash Flow9.27 Book Value$39.25 per share Price / Book2.24Miscellaneous Outstanding Shares118,360,000Free FloatN/AMarket Cap$10.39 billion OptionableNot Optionable Beta0.75 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:BMXMF) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioMerieux Please log in to your account or sign up in order to add this asset to your watchlist. Share bioMerieux With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
